Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,446 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06990464RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Fuzhou, FujianAges 18–75 - NCT06979674RecruitingPhase 1
ESG406 for advanced solid tumors
This trial tests a new drug called ESG406 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06512116RecruitingPhase 1
Testing SIBP-A17 for advanced solid tumors with HER2
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Birmingham, AlabamaAges 18 years+ - NCT05841563RecruitingPhase 1
PM54 for advanced solid tumors after limited treatment options
This Phase 1 trial tests PM54, a study drug, in people with advanced (cancer that has spread) solid tumors when standard treatments are no longer working. It focuses on safety and early signs of how well the treatment may work in specific cancer types.
San Antonio, TexasAges 18 years+ - NCT06298058RecruitingPhase 1
SIBP-A13 injection for advanced solid tumors
This trial tests a new drug called SIBP-A13 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for different cancer types, including lung, breast, and head and neck cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06178614RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06115642Enrolling by invitationPhase 1
Study of HLX43 for advanced solid tumors
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Stanford, CaliforniaAges 18–75 - NCT02215928Recruiting
Using tumor genetic tests to guide treatment choices
This study looks at your tumor’s genetic information to help doctors recommend treatment for cancers that have spread. It may help you get the most suitable therapy based on what’s found in your tumor.
Palo Alto, CaliforniaAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
Engineered immune cells for advanced melanoma or lung cancer
This trial tests a new treatment called OBX-115, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Scottsdale, ArizonaAges 18 years+ - NCT07630168RecruitingPhase 2
Does infusion timing affect treatment response in solid tumors?
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
Chapel Hill, North CarolinaAges 18 years+ - NCT07407582RecruitingPhase 1/Phase 2
Sodium thiosulfate to protect hearing during cisplatin chemo
This trial tests whether a medicine called sodium thiosulfate can protect your hearing from the side effects of cisplatin chemotherapy. It is for people with newly diagnosed cancer who are about to receive cisplatin for the first time.
Tucson, ArizonaAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of a new drug for advanced stomach, esophagus, or pancreas cancer
This trial tests a new medication that targets a specific protein (CLDN18.2) found on some cancer cells. It may help people with advanced or metastatic stomach, esophageal, or pancreatic cancer who have already tried other treatments.
Jacksonville, FloridaAges 18 years+ - NCT05539677Recruiting
Research biobank and patient registry for aggressive solid tumors
This study builds a biobank and patient registry using tumor samples and blood. It helps researchers better understand aggressive cancers and may improve future treatments by testing immune (defense) responses.
Saint PetersburgAges 1 year+ - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT06632262RecruitingPhase 2
Testing new drugs for cancers with FGFR gene changes
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
Guiyang, GuizhouAges 18 years+ - NCT07560943RecruitingPhase 1
AI-Designed Cancer Vaccine for Advanced Solid Tumors
This trial tests a new mRNA vaccine designed by artificial intelligence to treat advanced cancers that have stopped responding to standard chemotherapy. The vaccine is personalized to each patient's tumor and aims to help the immune system fight remaining cancer cells.
Chengdu, SichuanAges 18–70 - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,446 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.